TULSA, Okla. — Central States Research in South Tulsa is participating in the AHEAD Study that aims to help prevent Alzheimer’s disease.
Dr. Sarah Land, owner of Central States Research, LLC, says the experimental drug called B-A-N 2-4-0-1 attacks amyloid plaques that build up in the brain and eventually lead to Alzheimer’s.
“Part of the way we hope these drugs can work is to either prevent the formation of these plaques or reduce the development over time,” said Dr. Land.
The study is seeking participants that are either ages 55 to 65 and have a first degree relative with Alzheimer’s, or ages 65 to 80 and do not have to have a first degree relative with Alzheimer’s. Participants cannot already be diagnosed with Alzheimer’s but do have to have amyloid plaque buildup in their brain, which is determined through test conducted during the study.
Rita Nye, who is a participant in the study, lost her father Paul to Alzheimer’s when he was 84-years old.
“I’m hoping that yes, it will help me and that yes, I won’t.. if it has a cure, I will be ecstatic. Even if it doesn’t, as a nurse, a retired nurse, I hope I can help future generations,” said Nye.
Nye says she has already started to experience some of the symptoms of Alzheimer’s, things like forgetting eggs on the stove, her purse at the store, and even not being able to recall the word for something.
“The biggest fear is that you’re just not who you were. They can kind of become just a shell of a person and I don’t want to be that and don’t want that for my husband,” said Nye.
Dr. Land says the study needs more participants and more diversity in their research clinic and other participating clinics in cities across the U.S. and around the world.
“Latinos and African Americans they are over represented in dementia populations and underrepresented in research and it’s so important to get those people in here,” said Dr. Land.
Central States Research is the only lab in Oklahoma participating in the study.
©2021 Cox Media Group